LLY
Eli Lilly and Company
LLY has the edge over NEO overall, supported by stronger fundamentals and lower modeled downside.
NEO
NeoGenomics, Inc.
NEO's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
NEO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Weak |
NEO's revenue is currently healthy, and its profitability is stable, but its cash flow and balance sheet are under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
NEO PE Valuation
NEO has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
NEO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for NEO, with profitability improving. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over NEO on earnings quality, reporting a profit while its opponent remains loss making.
NEO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.29 | — |
| Q3 2026 | -$0.25 | +$0.63 |
| Q2 2026 | -$0.40 | +$0.41 |
| Q1 2026 | -$0.77 | -$0.16 |
| Q4 2025 | -$0.84 | -$0.22 |
| Q3 2025 | -$0.88 | -$0.27 |
| Q2 2025 | -$0.81 | -$0.19 |
| Q1 2025 | -$0.61 | +$0.05 |
| Q4 2024 | -$0.62 | +$0.08 |
NEO is still losing money, but far less than before: $0.25 per share over the past year, against $1.28 at its worst in late 2022.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over NEO on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over NEO on profitability, with a higher operating margin.
NEO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $209.3M | +11% |
| Q2 2026 | $201.7M | +11% |
| Q1 2026 | $186.7M | +11% |
| Q4 2025 | $190.2M | +11% |
| Q3 2025 | $187.8M | +12% |
| Q2 2025 | $181.3M | +10% |
| Q1 2025 | $168M | +7.5% |
| Q4 2024 | $172M | +11% |
NEO's revenue has grown year over year for 19 quarters in a row: $209M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3.8% | +11 points |
| Q2 2026 | -4.8% | +21 points |
| Q1 2026 | -9.8% | +6.8 points |
| Q4 2025 | -7% | +3.6 points |
| Q3 2025 | -14% | -1.8 points |
| Q2 2025 | -26% | -13 points |
| Q1 2025 | -17% | +3 points |
| Q4 2024 | -11% | +1.2 points |
NEO's operating margin was −3.8% last quarter, up 11 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over NEO on cash generation, producing positive trailing cash flow while its opponent burns cash.
NEO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$20.7M | -3724% |
| Q2 2026 | $11.7M | -16% |
| Q1 2026 | -$13.1M | +$16.7M |
| Q4 2025 | -$6.5M | -$4.7M |
| Q3 2025 | $570K | +$2.1M |
| Q2 2025 | $14M | +1621% |
| Q1 2025 | -$29.8M | +$1.7M |
| Q4 2024 | -$1.8M | -117% |
NEO has burned cash in most quarters: −$29M over the past year, against −$17M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over NEO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
NEO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.7% | -2.2M shares |
| 1 year | +0.1% | +172K shares |
| 3 years | +2.3% | +2.9M shares |
| 5 years | +4.9% | +6M shares |
| Available history | +19% | +20.8M shares |
NEO has 129M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over NEO on leverage, with a lower net debt burden relative to earnings.
NEO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 14.9x | High |
| Q2 2021 | 14.7x | High |
| Q1 2021 | -6.3x | Net Cash |
| Q4 2020 | -2.7x | Net Cash |
| Q3 2020 | -4.0x | Net Cash |
| Q2 2020 | -9.4x | Net Cash |
| Q1 2020 | 0.5x | Very low |
| Q4 2019 | -1.6x | Net Cash |
NEO's net debt is about 15 years of its operating earnings (EBITDA), after holding more cash than debt a year ago.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
NEO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.5 | Neutral |
| Stochastic | 38.7 | Neutral |
NEO's weekly RSI is 56 (neutral) and its Stochastic is 39 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
NEO PE vs Healthcare Sector
| Metric | NEO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
NEO has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over NEO on trend strength, trading above more of its moving averages.
NEO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $17.3 | 4.2% below |
| 20 week MA | $16.7 | 0.8% below |
| 50 week MA | $12.9 | 28% above |
| 100 week MA | $11.3 | 46% above |
| 200 week MA | $13.4 | 24% above |
NEO has slipped below its 8- and 20-week averages, though it's still 24% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
NEO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.8 | $55.4 | +86% |
| 2021 | $55.4 | $34.3 | -38% |
| 2022 | $34.3 | $9.17 | -73% |
| 2023 | $9.17 | $16.2 | +76% |
| 2024 | $16.2 | $16.8 | +4% |
| 2025 | $16.8 | $12.3 | -27% |
| 2026 YTD | $12.3 | $16.5 | +35% |
NEO has the edge over LLY on returns for 2026, with the stronger performance.